Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy by pace of disease progression on prior endocrine-based therapy from DESTINY-Breast06 (Abstract LB1-04). Disclaimer: This video transcript has not been proofread or edited and may contain errors. DESTINY-Breast06 was a pivotal phase III trial that looked at T-DXd or trastuzumab deruxtecan, a HER2-directed ADC
